Is NCT04187105 recruiting in Chicago, IL?

Yes, NCT04187105 is currently enrolling participants at its Chicago, IL location. This acute leukemia clinical trial is accepting qualified participants.

How do I join the acute leukemia clinical trial in Chicago?

To join this clinical trial in Chicago, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Chicago clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Acute Leukemia Clinical Trial in Chicago, IL (Phase 2)

About This Acute Leukemia Study in Chicago

This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total Marrow Irradiation (IM-TMI).

Sponsor: University of Illinois at Chicago

Who Can Participate

Inclusion Criteria

Patient age 18-75 years

Related donor who is, at minimum, Human Leukocyte Antigen (HLA) haploidentical or mismatched unrelated donor.

Haploidentical: The donor and recipient must be identical in at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. A minimum match of 4/8 if using HLA-A,-B,-DRB1,-Cw, or 5/10 if using HLA-A,-B,-Cw ,-DRB1, and -DQB1, will be considered evidence that the donor and recipient share one HLA haplotype.

Unrelated donors: unrelated donors who are mismatched in one or more of the following loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1,HLA-DQB1- can be included with a maximum of 4/8 or 5/10 mismatches.

Eligible diagnoses are listed below. Patient must have one of the following:

Relapsed or refractory acute leukemia (including AML or ALL in CR2 and primary refractory leukemia).

Poor-risk AML in first remission:

AML arising from MDS or a myeloproliferative disorder, or secondary AML

Poor risk molecular features including but not limited to presence of FLT3 internal tandem duplication mutation.

Poor-risk cytogenetics: Monosomal karyotype, complex karyotype (\> 3 abnormalities), inv(3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7

Poor risk ALL in first remission:

Poor risk cytogenetics: Philadelphia Chromosome, t(4;11), KMT2A translocation, t(8;14), complex karyotype (⩾ 5 chromosomal abnormalities) and low hypodiploidy (30-39 chromosomes)/near triploidy (60-78 chromosomes)

Philadelphia-like ALL

Presentation WBC \>30 × 109 for B-ALL or \>100 109 for T-ALL

Poor MRD clearance, defined as levels \>1 × 10-3 after induction and levels \>5 × 10-4 after early consolidation by flow cytometry

Myelodysplastic syndromes (MDS) with at least one of the following poor-risk features:

i. Poor-risk cytogenetics (including but not limited to 7/7q minus or complex cytogenetics)

ii. IPSS score of INT-2 or greater

iii. Treatment-related or Secondary MDS

iv. MDS diagnosed before age 21 years

v. Progression on or lack of response to standard DNA-methyltransferase inhibitor therapy

vi. Life-threatening cytopenias, including those generally requiring greater than weekly transfusions

vii. Poor risk molecular features including but not limited to the presence of BCOR, ASXL1, p53 or RUNX1 mutations

Mixed lineage and biphenotypic leukemia

Adequate end-organ function as measured by:

a. Left ventricular ejection fraction ≥ 40%

b. Bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST \< 5 x ULN

c. FEV1 and FVC \> 50% of predicted

Exclusion Criteria

Presence of significant co morbidity as shown by:

a. Left ventricular ejection fraction \< 40%

b. Bilirubin \> 2.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST \> 5 x ULN

c. FEV1 and FVC \< 50% of predicted or DLCO \<50% of predicted once corrected for anemia

d. Karnofsky score \<70

e. History of cirrhosis

Patients unable to sign informed consent

Patient who have previously received radiation to \>20% of bone marrow containing areas (assessed by radiation oncology physician)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT04187105) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Leukemia Treatment Options in Chicago, IL

If you're searching for acute leukemia treatment options in Chicago, IL, this clinical trial (NCT04187105) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced acute leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute leukemia clinical trials near you to find additional studies recruiting in your area.

Acute Leukemia Clinical Trial in Chicago, IL

Expert Care in Chicago

IRB Approved

No-Cost Care

Apply for This Chicago Location

Why Participate?

Simple Process